-
FRESCO-2 Study Sings ESMO, Re-Composing the "Life Fur Sound" in Patients with Advanced CRC
Time of Update: 2022-10-03
*For medical professionals onlyProfessor Li Jin and Professor Chen Gong take you to preemptively interpret the wonderful content of FRESCO-2 research!With the debut of FRESCO research at the 2017 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), fruquintinib has successfully ranked among the drug treatment of advanced colorectal cancer (CRC) in China and has become the "standard protocol" for the third-line treatment of patients with advanced CRC.
-
ESMO on-site direct attack After the progression of ositinib, ositinib combined treatment "re-challenge", fast response within 6 weeks, ORR exceeded 50%
Time of Update: 2022-10-03
Details are as follows: Professor Julien Mazieres 1 Background There is a lack of optimal treatment options after first-line ositinib therapy with advanced NSCLC of EGFR-sensitive mutations, and there is still a high degree of unmet clinical need.
-
【Nature Sub-journal】Zhu Zhenggang of Shanghai Jiao Tong University and other teams published a pangenomic analysis of gastric cancer in China
Time of Update: 2022-10-03
The researchers found that four distribution genes, ACOT1, GSTM1, SIGLEC14, and UGT2B17, exhibited extremely high deletion frequencies in gastric cancer populations.
The researchers found that four distribution genes, ACOT1, GSTM1, SIGLEC14, and UGT2B17, exhibited extremely high deletion frequencies in gastric cancer populations.
-
ESMO is directly attacking the new drug for rare tumor hard fibromas
Time of Update: 2022-10-03
DeFi is a global, phase III, randomized, double-blind, placebo (pbo)controlled trial (NCT03785964) in adults with progressive DT.
DeFi is a global, phase III, randomized, double-blind, placebo (pbo)controlled trial (NCT03785964) in adults with progressive DT.
-
Brainstem safe surgical approach associated microanatomy
Time of Update: 2022-10-03
Results of the studyThe authors provide an overview of the microanatomical and surgical approach safety of the 13 brainstem safety zones proposed by Professor Spetzler, including the anterior midbrain region, the lateral midbrain sulcus, the intercerebral region, the interthalamic region, the superior trigeminal nerve area, the peritrigeminal nerve area, the lateral pontineal region, the midbrain sulcus, the subthalamus, the suprathalamus, the olive region, the lateral medulla oblongation region and the anterolateral sulcus (Figures 1-7).
-
ESMO News: Innovative tumor therapy TILs cell therapy is coming, and clinical trials have been carried out!
Time of Update: 2022-10-03
org/meetings/esmo-congress-2022Click below to learn more about clinical trial programsWhen it comes to immunotherapy, people generally think of PD-1 or PD-L1 inhibitors, but immunotherapy includes a wide range of treatments, such as tumor-infiltrating lymphocyte (TILs) therapy.
-
Moving Forward in the Debate – 2022 ESMO Advances in Adjuvant Therapy for Kidney Cancer
Time of Update: 2022-10-03
prefaceIn recent years, postoperative adjuvant therapy for high-risk kidney cancer has been a hot topic in clinical research. The KEYNOTE564 study announced at the 2021 ASCO Conference confirmed for t
-
A novel drug for the treatment of glioblastoma in children
Time of Update: 2022-10-03
Johanna Wyss of the Aarau Children's Oncology Center in Switzerland and others introduced new drugs that can currently be used for GBM in children, and the article was published online in June 2022 in Cancers.
-
Cell: Zhejiang University found that the high-potassium environment in tumors can reshape tumor-associated macrophages
Time of Update: 2022-10-02
1" in the journal Cell Metabolism 。 In both mouse models and human samples, the study demonstrated that intratumor-high K+ regulates the functional polarization of tumor-associated macrophages (TAM) by targeting inward rectifying K+ channel Kir2.
-
J Clin Oncol: Risk and associated risk factors for subsequent heart failure in childhood cancer survivors
Time of Update: 2022-10-02
In summary, cancer survivors with an average cardiac radiation dose of ≥ 5 Gy have an increased risk of heart failure.
In summary, cancer survivors with an average cardiac radiation dose of ≥ 5 Gy have an increased risk of heart failure.
-
J Clin Oncol: busulfan vs systemic radiotherapy plus cyclophosphamide for acute B-lymphoblastic leukemia in adults
Time of Update: 2022-10-02
The study assessed the efficacy and toxicity of busulfan combined with cyclophosphamide (BuCy) and TBI in adult patients with B-cell ALL at the standard risk of obtaining the first complete response (CR1) for allo-HSCT.
-
Why do tumor patients have pathological fractures? How can it be prevented?
Time of Update: 2022-10-02
What should I do if I have a pathological fracture?After the occurrence of pathological fractures, it is necessary to seek medical attention in time, and when moving the affected limb, it is necessary to properly support and avoid the displacement of the fracture end.
-
Lancet Oncol: Selpercatinib can be expected in RET fusion-positive solid tumors
Time of Update: 2022-10-02
Progression-free survival and overall survivalAmong the 41 patients whose efficacy could be evaluated, the objective response rate was 43.
Progression-free survival and overall survivalAmong the 41 patients whose efficacy could be evaluated, the objective response rate was 43.
-
ESC 2022: First Phase III Results of Targeted KRAS G12C Sotorasib for NSCLC Released with an ORR of 28.1%
Time of Update: 2022-10-02
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio KRAS is the most common oncogene, with mutations in a variety of cancers (common cancers such as colon and lung, bile duct, small bowel, skin, bladder and breast, with a rate of pancreatic cancer mutations up to 90%).
-
J Gastroenterology: calcium-channel blockers may improve postoperative prognosis in patients with intrahepatic cholangiocarcinoma
Time of Update: 2022-10-02
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
-
Lancet Regional Health: The earlier the onset of diabetes, the higher the risk of pancreatic cancer!
Time of Update: 2022-10-02
The objective of the study was to estimate the incidence of pancreatic cancer in individuals with new-onset type 2 diabetes (T2DM) and to assess the relationship between pancreatic cancer risk and the age of onset and course of diabetes.
-
Clinical pharmacological basis of ADC
Time of Update: 2022-10-02
ADCs release effector molecules within the cell (non-cleavable linker) or in the circulatory system (cleavable linker) before reaching the tumor cell, and the unbound antibody and antibody fragments follow the metabolic pathway of the antibody to produce amino acids through enzymatic lysis and are reused by the body.
-
J Clin Oncol: Olaparib maintenance treatment for advanced ovarian cancer followed up to 7 years of overall survival prognosis
Time of Update: 2022-10-02
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
-
Consultation and analysis (2022.9.6): What is the most important and important thing to pay attention to to determine the benign and malignant nature of lung nodules?
Time of Update: 2022-10-02
Image display and analysis:Let's first look at three lesions of the right middle lobe with a 5 mm layer thick at different times:In February 2022, it was shown that the lung boundary of the right middle lobe tumor was clear, the ground glass density nodule was found, and the overall density sensory map was slightly higher, which was more consistent with carcinoma in situ or microinvasive adenocarcinoma from the image, and if it persisted, the probability of malignancy was greater.
-
Radiology: For women with a history of breast cancer, breast MRI screening may be easier!
Time of Update: 2022-10-02
Recently, a study published in the journal Radiology adjusted for confounding variables by using propensity score matching to compare the results of abbreviated breast MRI with full-protocol MRI in women with PHBC, providing technical support for further improving breast cancer detection rates.
